TEK receptor tyrosine kinase
Última actualización 18 Aug 2020
Cumple con las directrices editoriales
- DescargarDescargar
- Compartir
- Language
- Discusión
- Ask Patient
- Versión en audio
- Agregar a fuentes preferidas en Google
El TEK gene (also called the TIE2 gene) provides instructions for making a protein called TEK receptor tyrosine kinase. The TEK receptor tyrosine kinase (or TEK receptor) is active (expressed) mainly in endothelial cells, which line the walls of blood vessels. When the TEK receptor is activated, it triggers a series of chemical signals that facilitates communication between endothelial cells and smooth muscle cells. Layers of smooth muscle cells surround layers of endothelial cells lining the walls of blood vessels. Communication between these two cell types is necessary to direct blood vessel formation (angiogenesis) and ensure the structure and integrity of blood vessels.
Selecciones de videos para GenesBiblioteca de videos
Normal function
El TEK gene (also called the TIE2 gene) provides instructions for making a protein called TEK receptor tyrosine kinase. The TEK receptor tyrosine kinase (or TEK receptor) is active (expressed) mainly in endothelial cells, which line the walls of blood vessels. When the TEK receptor is activated, it triggers a series of chemical signals that facilitates communication between endothelial cells and smooth muscle cells. Layers of smooth muscle cells surround layers of endothelial cells lining the walls of blood vessels. Communication between these two cell types is necessary to direct blood vessel formation (angiogenesis) and ensure the structure and integrity of blood vessels.
The TEK receptor is also found in bone marrow, where it is expressed in blood-forming cells called hematopoietic stem cells. The role of the TEK receptor in hematopoietic stem cells is unknown. Researchers speculate that the TEK receptor aids in hematopoietic stem cell growth and division (proliferation) or cell specialization (differentiation).
Conditions referring to this gene or chromosome
Otros nombres
CD202B
soluble TIE2 variant 1
soluble TIE2 variant 2
TEK tyrosine kinase, endothelial
TEK tyrosine kinase, endothelial precursor
TIE-2
TIE2
Related patient information and medicines

Patient information leaflet
Cáncer de boca
Epidermal growth factor receptor monoclonal antibody (EGFR mAb) is one form of targeted therapy. Cetuximab is an EGFR mAb. Tyrosine kinase inhibitors (TKIs) are another. Immunotherapy is treatment that aims to boost the body's own immune system to destroy the cancer cells. It is also sometimes called biological therapy: Recombinant interleukin.

Patient information leaflet
Mastocitosis y trastornos de las células cebadas
If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on ... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new guidance on the use of midostaurin for people with mastocytosis..

Patient information leaflet
Leucemia mieloide crónica
Treatment for the initial chronic phase The aim of treatment is to control the disease process, to ease any symptoms and to prevent (or delay) the progress... You may be advised to have one or more of the following treatments: Imatinib tablets. This medicine is known as a tyrosine kinase inhibitor. The chemical tyrosine kinase is made by the.

Patient information leaflet
Miastenia gravis
Myasthenia gravis (MG) es un condition dónde muscles become easily tired and weak. It is due to a problem with how the nerves stimulate the muscles to tighten (contract). The muscles become easily tired and weak. What causes myasthenia gravis. Myasthenia gravis is an autoimmune disease. This means that the immune system The immune system (which.

Patient information leaflet
Pruebas de función hepática
They include substances that are made in the liver or affected by the health of the liver cells, chemicals which are processed or excreted by the liver, and hormones that the liver makes in order to. What are liver function tests used for. Gamma GT. Cinasa de creatina. Low levels of total protein can sometimes be seen in severe liver disease, in.

Patient information leaflet
¿Puedo tomar Chaga y Cordyceps juntos?
Taking chaga and cordyceps together ma... Caffeine Cordyceps may have mild stimulant properties and can interact with adenosine receptors. Using other medicines Taking multiple medicines. Nuestro Medicines Interaction Checker helps tú check whether your prescriptions, over-the-counter medicines, y suplementos son seguros a take together. Disclaimer.
Lecturas adicionales y referencias
- TEK receptor tyrosine kinase; MedlinePlus, National Library of Medicine.
- Brouillard P, Vikkula M. Genetic causes of vascular malformations. Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R140-9. doi: 10.1093/hmg/ddm211. Epub 2007 Jul 31.
- Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res. 2006 Mar 10;312(5):630-41. doi: 10.1016/j.yexcr.2005.09.002. Epub 2005 Oct 12.
- Limaye N, Boon LM, Vikkula M. From germline towards somatic mutations in the pathophysiology of vascular anomalies. Hum Mol Genet. 2009 Apr 15;18(R1):R65-74. doi: 10.1093/hmg/ddp002.
- Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, Eklund L, Boon LM, Vikkula M. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet. 2009 Jan;41(1):118-24. doi: 10.1038/ng.272. Epub 2008 Dec 14.
- Morris PN, Dunmore BJ, Tadros A, Marchuk DA, Darland DC, D'Amore PA, Brindle NP. Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations. J Mol Med (Berl). 2005 Jan;83(1):58-63. doi: 10.1007/s00109-004-0601-9. Epub 2004 Oct 29.
- Natynki M, Kangas J, Miinalainen I, Sormunen R, Pietila R, Soblet J, Boon LM, Vikkula M, Limaye N, Eklund L. Common and specific effects of TIE2 mutations causing venous malformations. Hum Mol Genet. 2015 Nov 15;24(22):6374-89. doi: 10.1093/hmg/ddv349. Epub 2015 Aug 28.
- Seront E, Boon LM, Vikkula M. TEK-Related Venous Malformations. 2008 Sep 18 [updated 2023 Mar 2]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1967/
- Seront E, Queisser A, Boon LM, Vikkula M. Molecular landscape and classification of vascular anomalies. Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):700-708. doi: 10.1182/hematology.2024000598.
- Seront E, Van Damme A, Coulie J, Boon LM, Vikkula M. Current and emerging pharmacotherapies for treating vascular malformations. Expert Rev Clin Pharmacol. 2026 Apr;19(4):289-302. doi: 10.1080/17512433.2026.2641807. Epub 2026 Mar 17.
- Soblet J, Kangas J, Natynki M, Mendola A, Helaers R, Uebelhoer M, Kaakinen M, Cordisco M, Dompmartin A, Enjolras O, Holden S, Irvine AD, Kangesu L, Leaute-Labreze C, Lanoel A, Lokmic Z, Maas S, McAleer MA, Penington A, Rieu P, Syed S, van der Vleuten C, Watson R, Fishman SJ, Mulliken JB, Eklund L, Limaye N, Boon LM, Vikkula M. Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations. J Invest Dermatol. 2017 Jan;137(1):207-216. doi: 10.1016/j.jid.2016.07.034. Epub 2016 Aug 9.
- Soblet J, Limaye N, Uebelhoer M, Boon LM, Vikkula M. Variable Somatic TIE2 Mutations in Half of Sporadic Venous Malformations. Mol Syndromol. 2013 Apr;4(4):179-83. doi: 10.1159/000348327. Epub 2013 Mar 26.
- Sudduth CL, Konczyk DJ, Smits PJ, Eng W, Al-Ibraheemi A, Upton J, Greene AK. Bockenheimer disease is associated with a TEK variant. Cold Spring Harb Mol Case Stud. 2021 Dec 9;7(6):a006119. doi: 10.1101/mcs.a006119. Print 2021 Dec.
- Vikkula M, Boon LM, Carraway KL 3rd, Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, Mulliken JB, Olsen BR. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 1996 Dec 27;87(7):1181-90. doi: 10.1016/s0092-8674(00)81814-0.
Comparte tus pensamientos o experiencias con otros en nuestro comunidades de pacientes.
Suscríbete al boletín de Patient
Tu dosis semanal de consejos de salud claros y confiables, escritos para ayudarte a sentirte informado, seguro y en control.
Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.

